Thank you for standing by, and welcome to the Phibro Animal Health Corporation Q4 2020 Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer I would now like to hand the conference over to your speaker today, Damian Spino, Chief Financial Officer. Thank you. Please go ahead, sir.
Thank you, Rebecca. Good morning, and welcome to the Phibro Animal Health earnings call for our Q4 year ended June 30, 2021. My name is Damian Finio, and I'm Chief Financial Officer of Fibro Animal Health Corporation. I'm joined on today's call by Jack Benheim, Fibro's Chairman, President and Chief Executive Officer and Daniel Benheim, Director and Executive Vice President of Corporate Strategy. On today's call, we will cover financial performance for the Q4 and our full fiscal year 2021 as well as guidance for our fiscal year ending June 30, 2022.
At the conclusion of our opening remarks, we will open the line for questions. I'd like to remind you that we are providing a simultaneous webcast of this call on our website, ta hc.com. Also on the Investors section of our website, you will find copies of the earnings press release and annual report on Form 10 ks filed with the SEC yesterday as well as the transcript and slides presented on this call. Our remarks today will include forward looking statements and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward looking statements section in our Earnings Press Release.
Our remarks include references to certain financial measures, which were not prepared in accordance Release for our discussion of these measures. Reconciliations of these non GAAP financial measures to the most directly comparable U. S. GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis.
Our adjusted results exclude acquisition related items, unusual non operational or non recurring items, including stock Based compensation and restructuring costs, other income, expense as separately reported in the consolidated statements of And lastly, income tax effects related to pre tax adjustments and unusual or non recurring income tax items. Now let me introduce our Chairman, President and Chief Executive Officer, Jack Benhime to share his opening remarks, which will include his perspective on the Q4, full year financial performance and guidance for our fiscal year 2022. Jack?
Thank you, Damian, and hello, everyone. I am pleased to announce that we ended our fiscal year strong, posting our 4th consecutive quarter of net sales growth and financial results ahead of our previously communicated Objections. Net sales for the quarter were up 19% versus a year ago, while full year sales were up 4%. Adjusted EBITDA for the quarter was up 13%, while full year adjusted EBITDA was up 6%. I will be proud of these numbers under any circumstances, but as we all know too well, the year ending June 30, 20 21 was one filled with unprecedented challenges for our industry.
Quarantines, lockdowns and political unrest around the world drove input prices higher, significant shipping delays and labor shortages, which required all of us to work that much harder and be that much more innovative. Our employees really stepped up, and I want to acknowledge our significant efforts, which enabled our organization to not only survive, but grow during these turbulent times. Our efforts to build a companion animal franchise are progressing. Sales of our canine growth joint care product, REGENZA, Continued to grow, in fact, doubling again in the second half of the year. Our plan going forward is to continue working with our exclusive distribution partner, while at the same time expanding our direct sales force in order to service veterinary clinics with the intent to double sales of REGENZA again in our upcoming fiscal year.
And behind Regensta, we completed a quarter of 3 progress on our pet product development pipeline, specifically in terms of our Dermacare and oral care products. We are optimistic these products will propel our growth in the mid- to long term. We made significant efforts to better streamline our business and financial process to strengthen our internal control framework. Although we've been in business since 1946, we went public in 2014. After running our business as a privately held company for nearly 70 years, Coupled with the diversity and complexity of our product offering and geographic spread of our facilities, gaining compliance under the Sarbanes Oxley Act in 2,002 These added some challenges to our organization.
But as you'll read in our annual Form 10 ks filed yesterday with the SEC, Our material weaknesses have been fully remediated, and we are now fully in compliance with the SOCK Act. Now let me share a few thoughts on the current state of the business and what we plan to deliver on our fiscal year ahead. Since the beginning of the global pandemic, our We continue to sell our products in over 80 countries across all species of Feed Animal. It's the diversity of our portfolio that enabled us to keep our business stable and on a path to modest growth. The most challenging conditions we face as a business are in those countries where the economies are struggling.
We expect this visibility by We remain confident that the diversity of our product portfolio will keep 5 0 on a course of growth While we continue making investments in our future. For our fiscal year 2022, we are projecting net sales in the range of $840,000,000 to $870,000,000 which reflects growth of approximately 1% to 4% And adjusted EBITDA of $110,000,000 to $114,000,000 reflecting about 2% to 6% growth. I'm excited that Despite our increased spend on future projects, we are in a position to lever our organization to see greater bottom line margin expansion. Overall, it was a great quarter and a solid year all around. We are projecting top and bottom line growth next year despite the continued challenges of the pandemic.
Now let me hand the call back to Damian to go through these items in more detail. Damian?
Thanks, Jack. Let me start with our consolidated financial performance for the Q4 ended June 30, 2021 versus the same quarter 1 year ago. Now keep in mind, the quarter ending June 30, 2020 was The first full quarter impacted by the effects of COVID-nineteen. Fibro, like most others in our industry, were navigating through a time when consumer demands were Shifting and there were disruptions in the supply chain ranging anywhere from labor shortages to shipping delays and consequently we posted lower than expected top and bottom line That said, on a consolidated basis, our 4th quarter financial performance was significantly ahead of the prior period. Net sales increased 19%, driven by improvements across all three of our business segments, namely Animal Health, Mineral Nutrition and Performance Products.
GAAP based net income and diluted earnings per share were up 203% 200% versus the same quarter a year ago. Although a portion of the In the prior quarter, our financial results included unanticipated adjustments relating to federal, global and tangible low tax income tax expense, often referred to as the GILTI tax, coupled with incremental reserves needed to cover uncertain international tax positions. These tax related adjustments recorded in the prior quarter were unfavorable to net income and earnings per share. Our current quarter results include similar tax related adjustments. However, these more recent tax related adjustments were favorable to net income and earnings per share, thus causing the large swing between prior quarter and current quarter provision for income tax.
After making our standard Adjustments to GAAP results, including acquisition related items, foreign currency movements and one offs such as the tax related adjustments I just described. 4th quarter adjusted EBITDA, adjusted net income and adjusted diluted EPS were up 13%, 89% and 88%, respectively. Turning to Slide 5, looking at the same financial metrics, but now for the full year. On a consolidated basis, our full year financial performance improved over the prior Net sales increased 4%, driven by stronger net sales performance for each of our 3 business segments. GAAP based net income and diluted EPS for the full year were up considerably versus the prior year.
Consistent with what drove the 4th quarter variance, The year over year variance was driven by sales and gross profit improvement as well as the delta between the tax related adjustments I mentioned previously, offset partially by increases in SG and A costs on strategic investments and interest expense. Now let's Dig a bit deeper into Q4 and full year financial performance for each of our business segments. On Slide 6, I'll start with 4th quarter financial performance for our largest segment, Animal Health, which is comprised of MFAs and other nutritional specialties and vaccine. Net sales of our Animal Health segment increased 20% versus the same quarter prior year. The increase in our Animal Health segment net sales is comprised of 3 components.
1st, The 26% increase in MSAs and other versus the prior quarter, driven by stronger demand across geographies and species. 2nd, 18% growth in nutritional specialties driven by strong domestic and international growth in dairy products and third, a 1% improvement in vaccine net sales driven primarily by growth in North America and Asia Pacific, offset partially by lower demand in Eastern Europe due to continuing economic challenges. In terms of profitability, Animal Health adjusted EBITDA was $29,500,000 which was Consistent with the same quarter prior year as higher gross profits were offset by increases in SG and A costs. Now on Slide 7, looking at full year financial performance for our Animal Health segment. Net sales for the full year increased 4% versus the prior year.
The increase in Animal Health full year net sales was driven by a 2% increase in MFAs and other versus the prior year, primarily due to domestic growth in swine coupled with increased international sales in poultry. 10% growth in nutritional specialties driven international growth in dairy products, partially offset by lower demand in domestic poultry. And lastly, the 3% decline net sales as domestic volume growth and increased demand in our Asia Pacific region was more than offset by challenging economic conditions in Eastern Europe. In terms of profitability, Animal Health adjusted EBITDA was $124,000,000 up 1% in comparison to the prior year, driven by increased gross profit, offset partially by higher SG and A costs. Moving on to Q4 financial performance for our other segments on Slide 8.
Mineral Nutrition net sales for the 4th quarter were $56,800,000 an increase of 14% versus the same quarter prior year driven by favorable product pricing correlated with the movement of the underlying raw material costs. Mineral Nutrition adjusted EBITDA was $4,700,000 an increase of 34% driven by increased gross profit on favorable customer and product mix And the adjusted EBITDA margin for the quarter was 8.2%, an improvement of 130 basis points versus a year ago. Our Performance Products segment continued to perform well, finishing the year strong. Net sales of $16,700,000 for the 3 months ended June 30, 2021 reflects an increase of 23% over the same quarter prior year, driven by strong demand for copper based products and favorable product Pricing correlated with the movement of the underlying raw material costs. The increased gross profit drove $2,300,000 of adjusted EBITDA for the quarter, a 2 16% increase versus prior year and an adjusted EBITDA margin of 13.6%, also an improvement from 1 year ago.
Lastly, corporate expenses decreased 4% versus the same quarter prior year due to savings in SG and A costs, driven by lower professional fees, partially These segments on Slide 9, Mineral Nutrition net sales for the full year were $220,600,000 an increase of 3 versus the prior year driven by favorable product pricing correlated with the movement of the underlying raw material costs. Mineral Nutrition adjusted EBITDA $17,100,000 an increase of 17% driven by increased gross profit and favorable product mix. Adjusted EBITDA margin for the quarter was 7.8%, an improvement of 100 basis points versus a year ago. Our Performance Products segment had a great year. Net sales of $67,100,000 for fiscal year 2021, reflecting an increase of 14% over the prior year, driven by stronger demand and increased volume of copper based products sold.
The increased gross profit drove $9,400,000 of adjusted EBITDA for the quarter, a 108% increase over the prior year and an adjusted EBITDA margin of 14.1 percent, an improvement of 6 40 basis points. Lastly, corporate expenses increased 6% versus prior year, driven by incremental investments in our future, employee performance based incentives, Professional fees and IT related expenses offset partially by lower travel due to COVID-nineteen related restrictions. Turning to key capitalization related metrics on Slide 10. Our business provided nearly $30,000,000 of cash before financing activities for the full year. Our gross leverage ratio, which is calculated by dividing total debt of $393,000,000 by trailing 12 month Adjusted EBITDA of $108,000,000 has been stable and sits at 3.6 times at year end.
In terms of liquidity, we had $245,000,000 available at year end. This includes cash and short term investments of $93,000,000 and $152,000,000 of unused and available revolving credit reflective of the incremental credit secured when we amended our loan agreement on April 22, 2021. Please note the accessibility of available revolving credit is subject to leverage ratio limitations, which are outlined in the loan agreement. And lastly, consistent with the past several quarters, we announced a quarterly dividend of $0.12 per share or $4,900,000 That concludes our perspective on both 4th quarter and full year financial performance. So let's turn our attention to fiscal year 2022 financial guidance On Slide 11.
For fiscal year 2022, despite the lingering uncertainties in country by country variability relating to COVID-nineteen, We are projecting net sales in the range of $840,000,000 to $870,000,000 which reflects a growth rate of approximately 1% to 4%. These projections assume growth for each of our 3 business segments, but driven primarily by Animal Health. We are projecting adjusted EBITDA in the range of $110,000,000 to $114,000,000 which reflects a growth rate of 2% to 6%, despite an approximate $20,000,000 increase in SG and A, about half of which is earmarked for planned incremental fiscal year 2022 spend on future investments. Future investments include research and development projects as well as other strategic initiatives. Net income and diluted earnings per share are projected to decline 14% to 17% in of fiscal year 2021, which our fiscal year 2022 guidance assumes will not be repeated.
This leads to an adjusted net income in the range of $50,700,000 to $53,300,000 and a projected Adjusted diluted earnings per share in the range of $1.25 to $1.32 both of which reflect an improvement up to 4% at the high end of the range or a decline of 1% at the low end of the range. Net income and earnings per share guidance both on a GAAP And adjusted basis implies a return to a more normalized effective tax rate ranging from 29% to 31%. Just to give you a bit more color on what's driving our net sales growth projections for our Animal Health segment, keeping in mind that COVID-nineteen variants remain a risk, Let me share 3 key assumptions. 1, we will drive growth in Nutritional Specialties by expanding our portfolio and further leveraging our 2019 acquisition of Osprey. This will enable us to penetrate the microbials market and identify opportunities better integrate Osprey's capabilities into the broader fibro business.
2, our plan is to drive growth in our vaccines business by bringing new products to the market and expanding our sales efforts into new markets, replacing distributor sales models with direct sales strategies where possible and seeking opportunities to recover in those geographies facing economic challenges that hampered our efforts in fiscal year 2021. And 3, we intend to maintain our position in the medicated feed additives global market. Our guidance assumes an increase of operating expenses of about $20,000,000 or Roughly half of the increase relates to planned incremental spending on future investments, which include, but are not limited to, Efforts to progress our pipeline of companion animal products, develop a vaccine for African swine fever, the ongoing registration of products in new markets and the continued build out of our vaccine facility in Sligo, Ireland. We expect our first product registrations for the Sligo facility to be issued Lastly, our plans include an approximate $8,000,000 or 30% increase in capital expenditures, part of which relates to carryover projects from our last fiscal year, while the remainder relates primarily to further investments to increase our vaccine manufacturing capacity. And consistent with prior years with the exception of last year, which was impacted by COVID, due to the seasonality of our portfolio, we expect a decline in our So in summary, Our fiscal year 2022 financial guidance is as follows: net sales of approximately $840,000,000 to $870,000,000 Net income of approximately $45,000,000 to $47,000,000 diluted earnings per share of approximately $1.11 to $1.16 adjusted EBITDA of approximately $110,000,000 to $114,000,000 Adjusted net income of approximately $50,700,000 to $53,300,000 and lastly, adjusted diluted EPS of approximately $1.25 to $1.32 That concludes our opening remarks.
Rebecca, could you please open the line for questions?
Your first question comes from the line of Katy Tryhan with Credit Suisse.
Hi. Thank you for taking my question. Can you just maybe expand a little bit further about some of the demand trends across species, including poultry, And how to think about those or what's embedded in your guidance for fiscal year 2020?
Thanks for the question. As we look out towards our fiscal year, We are still sitting sort of in a renewed world of COVID. I mean, our initial thoughts So towards the end of fiscal year 2021 was this thing was sort of in hand pretty much, We've seen what's going on with the delta strain as increase Our concern and definitely what we see in the business environment around the world. In the U. S, Interestingly enough, we're sitting with the highest population of dairy cows than we have since 1994.
So it's about 94,000,000 dairy cows where historically, many years, we kept talking around 19,000,000, 91,000,000. Sorry, I'm saying and I'm going to $9,500,000 looking at the wrong sheet here. We're seeing the poultry business being strong, export demand being good and again talking domestically. And again, same thing for the Smart business. All of our customers in the United States are making money.
Around the world, it's a mixed bag. Damian mentioned The COVID related economic problems in the Far East, also same thing in South America. So it's our outlook has been really sort of tempered a bit by the pandemic, But we see continuing strong underlying demand for the business, and that's really the basis for these numbers.
Okay, got it. That's great. And then maybe on REGENZA, I know you mentioned that sales doubled, but can you I mean, how has that product trended relative to your internal expectations? And perhaps maybe what have been some key learnings then as You know you've entered the companion animal market. Thanks.
Hi. It's Donnie speaking. So I think REGENZA has largely met our expectations for the past year. Truthfully, pre pandemic, we were going at a faster clip As access to the vet was limited and has remained somewhat limited, our growth slowed relative to our initial expectations, But it's been consistently growing throughout the last 12 months and as we discussed in our guidance, We expect it to double again in the next 12 months. As far as Our learnings, it's probably hard to draw lessons from the current time period, but Clearly, getting access to the vet is the challenge, and there's multiple ways to do it, and we're still figuring out for ourselves the best way.
Right now, we're working with an exclusive distributor, and we're happy and pleased with the access distributor for the most part is getting. But we are also at the same time Adjusting and increasing the number of our direct sales reps who are working with our distributor and that will be a trend that will continue and truthfully it sets us up As we, in the years to come, expand our product portfolio, we will have a larger footprint on the ground to sell those products.
Your next question comes from the line of Michael Bryskin with Bank of America.
Thank you for taking the question. I want to follow-up on sort of the outlook in Animal Health. Could you give us a little bit more insight into your expectations for next Between, NFAs and other, between nutritional specialties and vaccines, is it safe to assume that Nutritional Specialties vaccines are back to that historical sort of high single digit, maybe 10% range and MFA is another is more of a Low single digit 2% to 3% result next year just sort of putting all the pieces together.
Let me start, Michael. So as I mentioned on a consolidated basis, Our sales growth next year ranges from 1% to 4%, which I would say reflects general market growth in the animal protein industry growth globally. I also mentioned that Animal Health would drive those growth numbers. So within our Animal Health segment, we have MFA and others, nutritional specialties and We see the majority of the growth coming from the nutritional specialty and vaccine product line. So nutritional specialties, we expect to be fueled With some of the mentions we made around our acquisition of Osprey and some other products recently launched.
And in vaccines, we hope to recover in some of those Where we rest all economic challenges in 2021 and also launched some new products and expand existing products into new markets.
Okay. Okay. That's helpful. And then on the gross margin line, you saw some nice gains this quarter. I think a lot of that was probably impact of Do you anticipate gross margin to sort of continue along that trajectory next year?
Could you give us any sense on sort of your assumptions around COGS? Also keep in mind Inflationary pressures, everything else going on in the broader economy.
As we Put out these numbers as I was saying earlier. The challenges we face, generally, we feel gross margins should improve. The unknowns The commodity price increases we're seeing around the world, the unusual situation with shipping and freight Freight costs, some way it's tripling, quadrupling. And what impact that will have and our ability to pass that We will do it, but it's going to be a struggle. So in a normal year, I would say the answer is yes.
The margins will increase. We would see the 10 or greater percent in sales growth and in vaccines and in nutritionals and the lower growth in the MFA. But it's still an upside down market out there. And we still have not Have the ability in many countries to sit in front of the customer. Things are still going in a bit of a long distance.
So the information is slower, But overall, underlying growth is there, and We see it returning to trend. Whether it will completely return this year, fiscal year, not sure, but definitely returning.
Okay. Thanks so much.
And at this time, there are no further questions.
All right. Thank you, Rebecca. Thank you again to our employees for delivering such a strong financial performance in fiscal year 2021. And thank you everybody on today's call for your time, attention, questions and interest in Fibro Animal Health Corporation. Please enjoy these